Skip to content

EBIT at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$93.34M-46.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$59.78M-1.2%
HRO
HarrowHROW
-$22.08M-96.6%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.48M+34.3%
Merck & Co. logo
Merck & Co.MRK
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's EBIT?
EyePoint, Inc. (EYPT) reported EBIT of -$87.23M in Q1 2026.
How has EyePoint, Inc. 's EBIT changed year-over-year?
EyePoint, Inc. 's EBIT decreased by 78.6% year-over-year, from -$48.84M to -$87.23M.
What is the long-term trend for EyePoint, Inc. 's EBIT?
Over 4 years (2021 to 2025), EyePoint, Inc. 's EBIT has grown at a 44.9% compound annual growth rate (CAGR), from -$55.28M to -$243.43M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.